Clinical Trial

A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is designed to evaluate safety and anti-tumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-03-25; most recent amendment 2026-02-25.
Status change: Not Yet Recruiting → Recruiting 2025-07-20
Trial Details
NCT Number NCT06905197
Lead Sponsor Dizal Pharmaceuticals
Conditions Non Small Cell Lung Cancer
Enrollment 140 participants
Start Date 2025-05-13
Primary Completion 2027-09 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-27